New Therapy For Relapsing-Remitting Multiple Sclerosis (RRMS) Developed by Merck Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis (RRMS) may have a solution thanks to a revolutionary therapy that promises to reduce outbreaks by 67% for up to four years, according to Luciano Rossetti, VP of Merck Pharmaceuticals. “It is a new oral therapy that…